HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Poland’s Adamed Secures Tadalafil Rx-To-OTC Switch In World First

Executive Summary

Poland becomes the first country in the world to allow erectile dysfunction treatment tadalafil to be bought without a prescription thanks to a successful Rx-to-OTC switch application from local player Adamed Pharma.

You may also be interested in...



German Government Wants Sildenafil, Tadalafil OTC

Germany's Ministry of Health surprised all those present at a recent BAH meeting by announcing it would like to see erectile dysfunction drugs like sildenafil and tadalafil available OTC. Such a move, however, would put the government at odds with drug regulator BfArM's Expert Committee for Prescription, which recently rejected an application for the Rx-to-OTC switch of sildenafil. 

Honey Sachets Are Latest Sweet Spot For Selling Products With Undisclosed ED Drugs In US

FDA's warnings to four companies selling honey sachets containing undisclosed ED ingredients are latest examples of businesses marketing noncompliant products because the agency doesn't have sufficient funding to regulate the market, says University of Connecticut pharmacy professor Michael White.

Why Did Germany Reject Sildenafil OTC Switch?

Sildenafil was rejected at Germany’s independent switch committee’s most recent meeting. HBW Insight examines some of the arguments for and against the switch put forward by the regulator, members of the committee and the applicant, as recorded in the recently published minutes.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel